History of hypertension only if managed effectively on a stable regimen of two or fewer antihypertensives for at least three (3) months prior to screening
You may not be if
Females who were breastfeeding
Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study
Positive test at Screening for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab.
History of any other clinically significant chronic liver disease
Treatment with herbal/natural remedies with antiviral activity within 30 days prior to baseline.
Significant history of immunologically mediated disease, cardiac or pulmonary disease, seizure disorder or anticonvulsant use
History of ascites, variceal hemorrhage, hepatic encephalopathy, or conditions consistent with decompensated liver disease
Use of medications associated with QT prolongation within 30 days prior to dosing
Screening electrocardiogram (ECG) QTc value greater than 450 ms and/or clinically significant ECG findings
Personal or family history of Torsade de pointes.
Positive results for drugs of abuse test at screening
Abnormal hematological and biochemical parameters, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 5 times the upper limit of the normal range (ULN)
History of major organ transplantation with an existing functional graft
History of uncontrolled thyroid disease or abnormal thyroid-stimulating hormone (TSH) levels at screening
Clinically significant drug allergy to nucleoside/nucleotide analogs
History or current evidence of psychiatric illness, immunologic disorder, pulmonary, cardiac disease, seizure disorder, cancer or history of malignancy that in the opinion of the investigator makes the patient unsuitable for the study
History of systemic antineoplastic or immunomodulatory treatment within 6 months prior to dosing, or the expectation of such treatment during the study
